Tauriga Sciences Inc. Generates Record Weekly Net E-Commerce Sales

Rhea-AI Summary

Tauriga Sciences, Inc. (TAUG) reported record net E-Commerce sales exceeding $22,000 for the week of November 22-28, 2021, marking a significant milestone. This revenue surge is attributed to innovative product offerings and an increase in repeat customer orders. The company anticipates achieving record quarterly revenue for its 3rd Fiscal Quarter 2022, confidently citing strong growth in its high-margin E-Commerce segment. Additionally, Tauriga congratulates Aegea Biotechnologies for completing clinical validation of its COVID-19 test, in which Tauriga holds a meaningful equity stake.

Positive

• Record weekly net E-Commerce sales exceeding $22,000 for the week of November 22-28, 2021.
• Anticipated record quarterly revenue for the 3rd Fiscal Quarter 2022, indicating strong business growth.
• Growth driven by innovative product offerings and increased repeat customer orders.

Negative

• None.

For the Following Weekly Period: November 22nd-28th, 2021 or Thanksgiving Week 2021

NEW YORK, NY, Nov. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has generated record weekly net E-Commerce revenue (“sales”), for the following period: Monday November 22, 2021 through Sunday November 28, 2021. The Company’s net E-Commerce sales, for this one-week period, have exceeded $22,000 for the first time.  The Company is confident about its business prospects for the remainder of Calendar Year 2021 and beyond. 

Throughout its current operating Quarter (3^rd Fiscal Quarter 2022), the Company has experienced an acceleration in revenue growth – concerning its highest margin E-Commerce business segment.  Driving this revenue growth are several important factors: innovative product offerings, increased orders from repeat customers, and aggressive new marketing strategies. 

The Company is firmly on track to generate record quarterly revenue (net revenue), for its 3^rd Fiscal Quarter 2022.  The Company expects that net revenue generated for this quarter, when completed, will be substantially greater than any other previous quarter.  

Please visit the Company’s recently upgraded E-Commerce website, at:   https://taurigum.com

Lastly, the Company wishes to congratulate Aegea Biotechnololgies, Inc. (“Aegea”) on the completed clinical validation for its new COVID-19 Assay (“Test”).  Tauriga Sciences, Inc. currently holds a meaningful equity stake in Aegea.  

** Please Note: 3^rd Fiscal Quarter 2022 (Period: October 1, 2021 – December 31, 2021)

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (DELTA 8 THC Infused Tauri-Gum™ Flavor: Evergreen Mint), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative.  This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.

The Company is headquartered in Wappingers Falls, New York.  In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.

DISCLAIMER -- Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

Tauriga Sciences, Inc.

4 Nancy Court, Suite 4

Wappingers Falls, NY 12590

Chief Executive Officer

Mr. Seth M. Shaw

Email: sshaw@tauriga.com

cell # (917) 796 9926

Company Instagram: @taurigum

Personal Instagram: @sethsms47

Twitter: @SethMShaw

Corp. Website:   www.tauriga.com

E-Commerce Website:  www.taurigum.com

FAQ

What were Tauriga Sciences' E-Commerce sales figures for the week of November 22-28, 2021?

Tauriga Sciences reported E-Commerce sales exceeding $22,000 for the week of November 22-28, 2021.

What is the forecast for Tauriga Sciences' revenue in the 3rd Fiscal Quarter 2022?

Tauriga Sciences expects to achieve record quarterly revenue in the 3rd Fiscal Quarter 2022.

How is Tauriga Sciences driving revenue growth?

Tauriga Sciences is driving revenue growth through innovative product offerings, increased repeat customer orders, and aggressive marketing strategies.

What significant announcement did Tauriga Sciences make regarding Aegea Biotechnologies?

Tauriga Sciences congratulated Aegea Biotechnologies on completing clinical validation for its COVID-19 assay, in which Tauriga holds a meaningful equity stake.